↓ Skip to main content

A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin®) in cancer patients

Overview of attention for article published in Cancer Chemotherapy & Pharmacology, March 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#42 of 1,715)
  • High Attention Score compared to outputs of the same age (87th percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

blogs
1 blog
twitter
4 tweeters

Citations

dimensions_citation
84 Dimensions

Readers on

mendeley
102 Mendeley
Title
A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin®) in cancer patients
Published in
Cancer Chemotherapy & Pharmacology, March 2013
DOI 10.1007/s00280-013-2151-8
Pubmed ID
Authors

Masashi Kanai, Yoshihiko Otsuka, Kazunori Otsuka, Maremi Sato, Takafumi Nishimura, Yukiko Mori, Michiya Kawaguchi, Etsuro Hatano, Yuzo Kodama, Shigemi Matsumoto, Yoshiki Murakami, Atsushi Imaizumi, Tsutomu Chiba, Jun Nishihira, Hiroyuki Shibata

Abstract

A growing number of preclinical studies have demonstrated that curcumin could be a promising anticancer drug; however, poor bioavailability has been the major obstacle for its clinical application. To overcome this problem, we developed a new form of curcumin (Theracurmin) and reported high plasma curcumin levels could be safely achieved after a single administration of Theracurmin in healthy volunteers. In this study, we aimed to evaluate the safety of repetitive administration of Theracurmin in cancer patients.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 102 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Canada 2 2%
Brazil 1 <1%
Unknown 99 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 19 19%
Student > Bachelor 16 16%
Student > Master 15 15%
Other 14 14%
Student > Ph. D. Student 10 10%
Other 28 27%
Readers by discipline Count As %
Medicine and Dentistry 39 38%
Unspecified 12 12%
Agricultural and Biological Sciences 12 12%
Biochemistry, Genetics and Molecular Biology 10 10%
Nursing and Health Professions 6 6%
Other 23 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 May 2017.
All research outputs
#1,404,280
of 12,220,852 outputs
Outputs from Cancer Chemotherapy & Pharmacology
#42
of 1,715 outputs
Outputs of similar age
#21,128
of 166,066 outputs
Outputs of similar age from Cancer Chemotherapy & Pharmacology
#2
of 28 outputs
Altmetric has tracked 12,220,852 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,715 research outputs from this source. They receive a mean Attention Score of 3.5. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 166,066 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.